Mymetics Corp (MYMX)

[Work Harder]

4.5. Viral virosome vaccines against cancer

Virosome therapeutic agents were developed more significantly in multimodal vehicles against advanced-stage cancer. Virosome is the desired carrier for immunogenic substances and chemotropic agent delivery in oncologic fields. Oncolytic viruses comprise natural and recombinant mutants that replicate in tumor cells and reinforce anti-tumor functions [85]. Virosome could make delivery tumor antigens, including Tumor-Specific Antigens (TSA) and Tumor-Associated Antigens (TAA). Virosome compression to the viral vector has much safety and is persuaded to be used. The HVJ; Sendai virus can serve as multimodal tools against cancer applications [86].

Several studies were mentioned on the virosome application in cancer therapy. Reconstituted influenza virus envelopes (virosomes) were used in several preclinical studies and clinical trials for cancer treatment, such as ovarian carcinoma (OVCAR-3). Viral HA membrane fusion activity was inhibited by PEG-derivatized lipids incorporation into the virosome membrane, and then FabP fragments of mAb 323/A3 (anti-epithelial glycoprotein-2) were conjugated to the distal end of PEG on the virosomes. This study suggested that influenza virosomes had desirable properties in cytosolic delivery [87]. Waelti et al. showed that the virosome densely covered with HA spikes, conjugated with HER-2/neu (p185her2) oncogene produced a new selective drug delivery system inhibiting tumor progression [88].

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/

85

https://pubmed.ncbi.nlm.nih.gov/17336432/